Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
24.02
-1.76 (-6.83%)
Jan 30, 2026, 4:00 PM EST - Market closed
Pelthos Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Pelthos Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $56.75, which forecasts a 136.26% increase in the stock price over the next year. The lowest target is $50 and the highest is $60.
Price Target: $56.75 (+136.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pelthos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $57 → $60 | Buy | Maintains | $57 → $60 | +149.79% | Jan 26, 2026 |
| Lake Street | Lake Street | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +108.16% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +149.79% | Dec 3, 2025 |
| Roth Capital | Roth Capital | Strong Buy Initiates $57 | Strong Buy | Initiates | $57 | +137.30% | Nov 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $50 → $57 | Buy | Reiterates | $50 → $57 | +137.30% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
19.36M
Revenue Next Year
68.56M
from 19.36M
Increased by 254.08%
EPS This Year
-17.51
from -14.27
EPS Next Year
-6.16
from -17.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27.0M | 93.2M | ||||
| Avg | 19.4M | 68.6M | ||||
| Low | 11.5M | 35.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 381.5% | ||||
| Avg | - | 254.1% | ||||
| Low | - | 85.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -10.95 | -1.10 | ||||
| Avg | -17.51 | -6.16 | ||||
| Low | -22.90 | -11.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.